Finance Home - My Yahoo - Yahoo! - Help

Saturday, December 5, 2009, 9:53PM ET - U.S. Markets Closed. Dow  0.22% Nasdaq  0.98%

Osiris Therapeutics, Inc. (OSIR)

On Dec 4: 6.99   0.15 (2.10%)

MORE ON OSIR

Quotes Summary Real-Time Options Historical Prices Charts Interactive Basic Chart Basic Tech. Analysis News & Info Headlines Financial Blogs Company Events Message Board Company Profile Key Statistics SEC Filings Competitors Industry Components Analyst Coverage Analyst Opinion Analyst Estimates Research Reports Star Analysts Ownership Major Holders Insider Transactions Insider Roster Financials Income Statement Balance Sheet Cash Flow

Profile Get Profile for:
Osiris Therapeutics, Inc. 7015 Albert Einstein Drive Columbia, MD 21046 United States - Map Phone: 443-545-1800 Fax: 443-545-1701 Web Site: http://www.osiristx.com DETAILS   Index Membership: N/A Sector: Healthcare Industry: Biotechnology Full Time Employees: 158 BUSINESS SUMMARY   Osiris Therapeutics, Inc., a stem cell therapeutic company, develops products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States. The company’s principal product includes Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn’s disease, and acute radiation syndrome; and in phase II clinical trials for the treatment of Type I diabetes mellitus, acute myocardial infarction, and chronic obstructive pulmonary disease. Its product also consists of Chondrogen, a Phase II clinical trial product for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for distributing Prochymal for the treatment of GvHD in Japan. The company was founded in 1992 and is headquartered in Columbia, Maryland. Key Statistics COMPANY WEBSITES   Home Page Search Yahoo! for: More on Osiris Therapeutics, Inc.		CORPORATE GOVERNANCE   Osiris Therapeutics, Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Dec-09 is better than 19.7% of Russell 3000 companies and 24.3% of Pharmaceuticals, Biotechnology & Life Sciences companies. Brought to you by Institutional Shareholder Services. View Financials KEY EXECUTIVES     Pay Exercised Mr. Peter Friedli , 48 Co-Founder and Chairman N/A N/A Dr. Charles Randal Mills Ph.D., 37 Chief Exec. Officer, Pres $ 688.00K $ 0 Mr. Philip R. Jacoby Jr., 58 Chief Financial Officer and Corp. Sec. $ 183.00K $ 45.00K Dr. Lode Debrabandere Ph.D., 45 Sr. VP of Therapeutics $ 314.00K $ 0 Dr. Michelle LeRoux Williams Ph.D., 34 Chief Scientific Officer $ 295.00K $ 0 Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year. View Insiders
Add to Portfolio     Set Alert     Email to a Friend Get Profile for Another Symbol: Symbol Lookup • Annual Reports • Sector Analysis